drugset
drugset / Trial / NCT04840745

The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1

NCT04840745 ↗

Phase 1 Unknown 32 enrolled Chong Kun Dang Pharmaceutical Severance Hospital · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

A randomized, single-blinded, parallel design phase I clinical trial to investigate the safety and pharmacokinetics/pharmacodynamics of CKD-841 A-1, CKD-841 D or Leuplin Inj. after subcutaneous injection in postmenopausal female

Timeline

Start
2021-04
Primary completion
2021-10
Completion
2021-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Leuprolide Other / unclassified 1.88 mg Subcutaneous
Subject Leuprolide Other / unclassified 2.92 mg Subcutaneous
Subject Leuprolide Other / unclassified 3.75 mg Subcutaneous

Indications

precocious puberty